COMMUNIQUÉS West-GlobeNewswire

Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
02/05/2024
Boston (May 2, 2024)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced the early [...]
EDAP to Announce First Quarter 2024 Financial Results on May 16, 2024
02/05/2024
Company to host conference call and webcast on Thursday, May 16 th at 8:30am EDT LYON, France, May 2, 2024 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today [...]
Intuity Medical’s POGO Automatic®, the First and Only FDA-Cleared Automatic Blood Glucose Monitor, Now Covered by Medicare Part B
02/05/2024
CMS establishes new Medicare coverage codes for the one-step automatic blood glucose monitor, expanding access to millions of seniors living with diabetes FREMONT, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Intuity [...]
PDS Biotech Appoints Stephan Toutain as Chief Operating Officer
02/05/2024
Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy [...]
Shape Therapeutics Announces Appointment of Matt Valentino as Chief People Officer
02/05/2024
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the appointment of Matt Valentino [...]
Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial
02/05/2024
Partnership with Leading Biotech Company Enrolls 28% of Study Participants with 22x Greater Enrollment Velocity Compared to Traditional Brick-and-Mortar Clinical Trial Sites RESEARCH TRIANGLE PARK, N.C., May 02, 2024 ( [...]
iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
02/05/2024
NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first [...]
Mangoceuticals Granted 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement and Conditional Approval of Compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement
02/05/2024
Dallas, Texas, May 02, 2024 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing, and selling a variety of men’s health and wellness products [...]
The Canadian Dermatology Association (CDA) Announces the Launch of the 2024 Shade Structure Grant Program
02/05/2024
Aiming to Combat Skin Cancer with Community Shade Initiatives OTTAWA, May 02, 2024 (GLOBE NEWSWIRE) -- The Canadian Dermatology Association (CDA) is thrilled to announce the return of the Shade Structure Grant Program, [...]
L’Association canadienne de dermatologie (ACD) annonce le lancement de l’édition 2024 de son Programme de subvention de structures ombrières
02/05/2024
Aider à prévenir les cancers de la peau par des initiatives destinées à créer de l’ombre dans les collectivités OTTAWA, 02 mai 2024 (GLOBE NEWSWIRE) -- L’Association canadienne de dermatologie (ACD) est ravie d’annoncer [...]
LifeMD Becomes the First Virtual Primary Care Provider to Elevate GLP-1 Patient Care with Real-time, At-Home Monitoring of Blood Pressure and Body Composition
02/05/2024
LifeMD and Withings Health Solutions partnership exemplifies the potential of digital health technology to transform virtual patient care and improve outcomes NEW YORK and BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- LifeMD [...]
Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024
02/05/2024
BASKING RIDGE, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of [...]
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
02/05/2024
Daré joins a nationwide network working to accelerate transformative health solutions SAN DIEGO, May 02, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today [...]
Amolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism
02/05/2024
Designation reflects the seriousness of the disease and the potential for eneboparatide to address the urgent need for new treatment options that address key treatment goals in hypoparathyroidism LYON, France and [...]
Amolyt Pharma obtient la désignation Fast Track de la FDA pour l'énéboparatide dans le traitement de l'hypoparathyroïdie
02/05/2024
Cette désignation atteste de la gravité de la maladie et du potentiel de l'énéboparatide pour faire face au besoin urgent de nouvelles options thérapeutiques répondant aux objectifs clés du traitement de l' [...]
PROPHASE LABS INC. TO PRESENT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 9
02/05/2024
GARDEN CITY, NY, May 02, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be presenting first quarter 2024 financial results on a virtual conference call hosted by Renmark [...]
Positive Initial Clinical Data Reported from Immutep’s Efti Combined with Radiotherapy and Checkpoint Inhibitor from Phase II Trial in Soft Tissue Sarcoma
02/05/2024
Media Release Novel triple combination of efti with radiotherapy and anti-PD-1 therapy is well tolerated and has led to encouraging initial efficacy data in EFTISARC-NEO Phase II trial Four of six patients treated have [...]
Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business Update
02/05/2024
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC [...]
Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)
02/05/2024
KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent [...]

Pages